Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study

World Journal of Surgical Oncology

Hiroyuki Shibata¹  Kyoko Nomura²  Katsutoshi Nakayama³  Yusuke Sato⁴  Satoru Motoyama⁴  Maiko Atari⁴  Yoshihiro Minamiya⁴  Tsubasa Matsuo⁴  Shinogu Takashima⁴  Kazuhiro Imai⁴ 

[1] Department of Clinical Oncology, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan;Department of Health Environmental Science and Public Health, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan;Department of Respiratory Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan;Department of Thoracic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan;

关键词: Carboplatin;    Gemcitabine;    Adjuvant chemotherapy;    Lung cancer;   

DOI  :  10.1186/s12957-020-02041-0

来源: Springer

【 摘 要 】

PurposeIn cases of non-small cell lung cancer (NSCLC), surgery remains the best option for cure, but surgery is of benefit only when the disease is localized. Although adjuvant chemotherapy reportedly has a significant beneficial effect on survival, the benefit of a carboplatin (CBDCA) regimen is unclear. We therefore investigated the efficacy and tolerability of CBDCA (area under the curve 5) plus gemcitabine (GEM, 1000 mg/m2) as adjuvant chemotherapy.MethodsA total of 82 pStage IB-IIIA NSCLC patients who had undergone complete resection and received adjuvant chemotherapy were analyzed retrospectively. Among them, 65 patients received CBDCA + GEM and 17 received CDDP + VNR. Propensity score analysis generated 17 matched pairs of both groups.ResultsSixty-five patients received CBDCA + GEM. Their 5-year relapse-free survival (RFS) and overall survival were 47.8% (median, 52.5 months) and 76.9% (median, 90.1 months), respectively. Toxicities, which included neutropenia, nausea/anorexia, fatigue, and vasculitis, were significantly milder than with CDDP + VNR. There were no significant differences in RFS between CBDCA + GEM and CDDP + VNR (p = 0.079) after matching for age, performance status, and pStage.ConclusionCBDCA + GEM was effective and well tolerated as adjuvant chemotherapy, with a manageable toxicity profile.

【 授权许可】

CC BY